CorMedix's Investment Fuels Talphera's Growth in Anticoagulation Therapy with Niyad™

Strategic Collaboration Enhances Talphera’s Growth Potential in Anticoagulation Therapy

Talphera, Inc., a specialty pharmaceutical firm focused on developing innovative therapies, appoints Joe Todisco, CEO of CorMedix Inc., to its Board of Directors, marking a significant step in its strategic development. This appointment, which comes in the wake of CorMedix's investment in Talphera during a private placement in September 2025, reflects the growing collaboration between the two companies. CorMedix’s investment not only allows it to nominate a board representative but also grants a 60-day exclusive negotiation period to explore an acquisition agreement with Talphera, contingent on positive outcomes from ongoing clinical studies.

The lead product under Talphera's pipeline, Niyad™, is a lyophilized formulation of nafamostat that is being evaluated as an anticoagulant for use in extracorporeal circuits. This investigational device has received Breakthrough Device Designation from the FDA, highlighting its potential to address unmet medical needs in critical care settings. The ongoing NEPHRO CRRT clinical study aims to establish Niyad™ as a new standard of care, and Talphera is optimistic about its approval prospects in 2026. The collaboration with CorMedix is anticipated to provide the strategic support necessary for Talphera to further advance its product development and commercialization efforts.

Adrian Adams, Chairman of Talphera’s Board, emphasizes the importance of Todisco’s extensive experience in the pharmaceutical industry, particularly in commercialization and portfolio expansion. His leadership is expected to enhance Talphera’s strategic direction as it aims to leverage the promising clinical outcomes of Niyad™. The partnership underscores a mutual commitment to advancing innovative therapies for medically supervised environments, positioning both companies for potential growth in a competitive market.

In addition to the leadership change, the collaboration aims to capitalize on the upcoming clinical results to solidify Talphera's market position. The focus on Niyad™ not only showcases Talphera's commitment to addressing critical therapeutic needs but also sets the stage for a potentially lucrative partnership with CorMedix. As both companies work together, they are poised to make significant strides in the field of anticoagulation therapy.

Overall, Talphera's strategic initiatives, bolstered by CorMedix's expertise and investment, signal a promising future for the development of Niyad™ and the broader goals of enhancing patient care in high-acuity medical settings.